Back

Cardiovascular-kidney-metabolic overlap and finerenone in heart failure: insights from the FINEARTS-HF Trial

31 August 2026 (14:40 - 14:50)
Organised by: Logo
Congress Presentation Part of: HFpEF: targeting the underlying pathophysiology Heart Failure with Preserved Ejection Fraction (HFpEF) ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor John Ostrominski

Brigham and Women's Hospital, Harvard Medical School, Boston (United States of America)

4 More presentations in this session

Presentation thumbnail
PRODH preserves myocardial energetic homeostasis and attenuates post-infarction remodeling
Doctor Z. Zhang (CN)
Abstract
Presentation thumbnail
Molecular mechanisms of diastolic heart failure: a study of myosin phosphatase regulatory subunit deficiency
Doctor M. Mccauley (Chicago, US)
Abstract
Presentation thumbnail
The classical- and alternative renin-angiotensin-aldosterone-system (RAAS) in HFpEF and cardiac amyloidosis - a cohort comparison of angiotensin profiles
Mr K. Kumar (AT)
Abstract
Presentation thumbnail
Characterisation of exercise responses in HFpEF stratified by ejection fraction: implications for therapeutic myosin modulation
Doctor R. Xavier (Oxford, GB)
Abstract

Access the full session

Session thumbnail
HFpEF: targeting the underlying pathophysiology

The Event

Event poster

ESC Congress 2026

31 August 2026 14:40 CET
You may be interested in
thumbnail
Congress Presentation
Cardio-Kidney-Metabolic Overlap in the FINEARTS-HF Trial
12 May 2024
thumbnail
Congress Presentation
Cardiovascular protection by combination of the selective nonsteroidal MR antagonist finerenone and the SGLT2 inhibitor empagliflozin in a preclinical model of hypertension-induced end-organ damage
27 August 2021
thumbnail
Congress Presentation
Highlights from FINEARTS-HF and FINE-HEART: the role of finerenone in heart failure
2 September 2024
thumbnail
Congress Presentation
Cardiovascular-kidney-metabolic syndrome and association with mortality in the UK Biobank prospective cohort study
1 September 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources